In this month’s article in Journal of Neurosurgery: Pediatrics, Mark Kieran and colleagues studied the frequency of brain imaging (through MRI) a patient receives to evaluate how often tumors recurred. They found that at either 2 or 5 years of recurrence-free survival there were no clinical symptoms or mortality observed in the patient population studied, proposing a reduction in the number of MRI scans a patient receives from 10 to 5, thus reducing the psychological and financial impact of post-operative care.
This month’s featured publication by Dr. Kieran discusses the medulloblastoma subgroup with activations of the sonic hedgehog pathway, the preclinical data currently known and the development of novel therapies to overcome chemoresistance.
In this e-book chapter, Dr Kieran discusses the signalling molecule BRAF, and how mutations in BRAF can cause pediatric brain cancer. Also explained is how our scientists are beginning to understand the biology of BRAF signalling, and how these discoveries can be exploited for new therapy targets.
In this review article, Drs. Stiles, Segal, Beroukhim, Ligon and Kieran discuss low grade glioma clinical features, current therapies and new genomic discoveries, and how these most recent findings can be applied to diagnose and treat low grade tumors in the future.
This paper, published in Pediatric Blood and Cancer, is a collaboration between work carried out in the laboratory of Rameen Beroukhim, MD, PhD and clinical data from Mark Kieran, MD, PhD. The researchers examined the long-term survival rates of adults who had low-grade gliomas as children. Here they show that patients with previous disease have an excellent long-term survival outcome, and treatment strategies should focus on disease management with minimal toxicity.
- [ Pubmed ]